SNRK

Aurora Kinase A, Pipeline Review, H2 2019 - AbbVie Inc, Cielo Therapeutics Inc & Taiho Pharmaceutical Co Ltd. - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020
Health, Pharmaceutical, Enzymes, Cell Cycle, Aurora A kinase, Cancer research, Protein kinase, Aurora kinase, SNRK, Casein kinases

The "Aurora Kinase A - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aurora Kinase A - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Aurora Kinase A - Pipeline Review, H2 2019'; Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules.
  • Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Aurora kinase A also known as serine/threonine-protein kinase 6 is an enzyme that contributes to the regulation of cell cycle progression.
  • The report 'Aurora Kinase A - Pipeline Review, H2 2019' outlays comprehensive information on the Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Serine Threonine Protein Kinase ATR, Pipeline Review, H2 2019 - Artios Pharma Ltd, Bayer AG, IMPACT Therapeutics Inc & Pfizer Inc - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020
Health, Pharmaceutical, Proteins, Branches of biology, Ataxia telangiectasia and Rad3 related, ATR, Biology, Phosphatidylinositol 3-kinase-related kinase, SNRK

The "Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019'; Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules.
  • Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Serine/threonine-protein kinase ATR is an enzyme encoded by the ATR gene.
  • It also reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.